A5067450698- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Malaria Research and Control
- Viral Infections and Outbreaks Research
- Virology and Viral Diseases
- Viral gastroenteritis research and epidemiology
- Dengue and Mosquito Control Research
- Hepatitis Viruses Studies and Epidemiology
- Respiratory viral infections research
- Liver Disease and Transplantation
- Immune responses and vaccinations
- Rabies epidemiology and control
- Hepatitis B Virus Studies
- Child Nutrition and Water Access
- Poxvirus research and outbreaks
- Heme Oxygenase-1 and Carbon Monoxide
- Insect symbiosis and bacterial influences
- Animal Virus Infections Studies
- Viral Infections and Immunology Research
- Pneumonia and Respiratory Infections
- Vector-Borne Animal Diseases
- COVID-19 epidemiological studies
- Legionella and Acanthamoeba research
- Vaccine Coverage and Hesitancy
- Vibrio bacteria research studies
Takeda (Switzerland)
2019-2025
Institut Pasteur de Bangui
2013-2024
Takeda (United States)
2023
Centro de Ingeniería Genética y Biotecnología
2023
Takeda (Japan)
2020
Takeda (Singapore)
2017
Institut Pasteur
2014
Oxford University Clinical Research Unit
2009-2012
Hospital for Tropical Diseases
2009-2012
Background There is currently no licensed antiviral drug for treatment of dengue. Chloroquine (CQ) inhibits the replication dengue virus (DENV) in vitro. Methods and Findings A double-blind, randomized, placebo-controlled trial CQ 307 adults hospitalized suspected DENV infection was conducted at Hospital Tropical Diseases (Ho Chi Minh City, Vietnam) between May 2007 July 2008. Patients with illness histories 72 hours or less were randomized to a 3-day course (n = 153) placebo 154)....
Abstract Background Takeda’s live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, we have reported its efficacy and safety both seronegative seropositive participants that performance varies by serotype, with some decline from first to second year postvaccination. This exploratory analysis provides an update cumulative third-year data. Methods Healthy 4–16 olds (n = 20099) were...
BackgroundAbout half of the world's population lives in dengue-endemic areas. We aimed to evaluate long-term efficacy and safety two doses tetravalent dengue vaccine TAK-003 preventing symptomatic disease any severity due virus (DENV) serotypes children adolescents.MethodsIn this ongoing double-blind, randomised, placebo-controlled trial, we enrolled healthy participants aged 4–16 years at 26 medical research centres across eight countries (Brazil, Colombia, Dominican Republic, Nicaragua,...
Dengue is a public health problem in many countries. Rapid diagnosis of dengue can assist patient triage and management. Detection the viral protein, NS1, represents new approach to diagnosis.The sensitivity specificity Platelia NS1 ELISA assay an lateral flow rapid test (LFRT) were compared against gold standard reference diagnostic algorithm 138 Vietnamese children adults. Overall, was modestly more sensitive (82%) than LFRT (72%) confirmed cases. Both assays for primary secondary dengue,...
Background Dengue is a major public health problem in tropical and subtropical countries. Exploring the relationships between virological features of infection with patient immune status outcome may help to identify predictors disease severity enable rational therapeutic strategies. Methods Clinical features, antibody responses markers were characterized Vietnamese adults participating randomised controlled treatment trial chloroquine. Results Of 248 patients laboratory-confirmed dengue...
Dengue is a major public health problem in tropical and subtropical countries. Rapid easy diagnosis of dengue can assist patient triage care-management. The detection DENV NS1 on rapid lateral flow tests offers fast route to presumptive but careful evaluations are urgently needed as more people use them. sensitivity specificity the Bio-Rad Ag Strip SD Duo (NS1/IgM/IgG) were evaluated panel plasma samples from 245 Vietnamese patients with RT-PCR confirmed 47 other febrile illnesses. had...
Dengue, the most common mosquito-borne viral infection of humans, is endemic across much world, including tropical Asia and increasing in its geographical range. Here, we present a mathematical model dengue virus dynamics within infected individuals, detailing interaction between simple immune response. We fit this to measurements plasma titre from cases primary secondary DENV 1 Vietnam. show that variation parameters governing response sufficient create observed individuals. Estimating...
Takeda's dengue vaccine is under evaluation in an ongoing phase 3 efficacy study; we present a 2-year update.Children (20 099, 4-16 years old) were randomized to receive 2 doses of TAK-003 or placebo months apart and are surveillance detect by serotype-specific RT-PCR.Cumulative against approximately 27 since first dose was 72.7% (95% confidence interval [CI], 67.1%-77.3%), including 67.0% CI, 53.6%-76.5%) dengue-naive 89.2% 82.4%-93.3%) hospitalized dengue. In the second year, decline...
Background In Sub-Saharan Africa, infectious diarrhea is a major cause of morbidity and mortality. A case-control study was conducted to identify the etiology describe its main epidemiologic risk factors among hospitalized children under five years old in Bangui, Central African Republic. Methods All consecutive for Pediatric Complex Bangui whom parent’s written consent provided were included. Controls matched by age, sex neighborhood residence each case For both cases controls, demographic,...
Yellow fever (YF) vaccination is often mandatory for travelers to YF-endemic areas. The areas with risk of YF partially overlap those dengue, which there currently no recommended vaccine available dengue-naïve individuals. This phase 3 study assessed the immunogenicity and safety concomitant sequential administration (YF-17D) tetravalent dengue (TAK-003) vaccines in healthy adults aged 18-60 years living US non-endemic either virus.Participants were randomized 1:1:1 receive following...
Abstract Background We explored the impact of prior yellow fever (YF) or Japanese encephalitis (JE) vaccination on efficacy Takeda's dengue vaccine candidate, TAK-003. Methods Children 4–16 years age were randomized 2:1 to receive TAK-003 placebo and under active febrile surveillance. Symptomatic was confirmed by serotype-specific reverse-transcription polymerase chain reaction. YF JE history recorded. Results Of 20 071 children who received placebo, 21.1% had a 23.9% at randomization....
Early formulations of Takeda's tetravalent dengue vaccine candidate (TAK-003) have demonstrated notably higher neutralizing antibody responses against serotype 2 than other serotypes. Here, we assessed the immunogenicity and tolerability in adults living Singapore two TAK-003 formulations: an early formulation, referred to as HD-TDV, a new formulation with 10-fold lower potency, TDV (NCT02425098).Subjects aged 21-45 years were stratified by baseline serostatus randomised 1:1 receive single...
Vaccination against hepatitis A virus (HAV) is largely recommended for travelers worldwide. Concurrent dengue and HAV vaccination may be desired in parallel to countries where both diseases are endemic. This randomized, observer-blind, phase 3 trial evaluated coadministration of vaccine with tetravalent (TAK-003) healthy adults aged 18-60 years living the UK.Participants were randomized (1:1:1) receive placebo on Day 1, 90 (Group 1), TAK-003 2), or 3). The primary objective was...
Abstract Background TAK-003 has been shown to be well tolerated and effective against symptomatic dengue disease hospitalization, irrespective of baseline serostatus. Most infections are asymptomatic/subclinical. This study assessed whether could protect asymptomatic/subclinical by evaluating increased neutrlizing antibody titers (NAb) after natural infection. Methods DEN-301(NCT02747927) is a phase 3 trial among 4- 16-year-old participants who received 2 doses TAK-003/placebo months apart....
In trials, dengue vaccine efficacy evaluation relies on participants presenting with febrile illness/clinically suspected contacting the study site for sample collection and clinical assessment within a short timeframe. Here, we present key considerations to maintain high compliance surveillance procedures in trial that assessed TAK-003 efficacy. DEN-301 (NCT02747927) is randomized phase 3 children/adolescents from eight dengue-endemic countries Latin America (LATAM) Asia-Pacific (APAC)....
Little is known about the rate at which genetic variation generated within intrahost populations of dengue virus (DENV) and what implications this diversity has for pathogenesis, disease severity, host immunity. Previous studies DENV have used a low frequency sampling and/or experimental methods that do not fully account errors through amplification sequencing viral RNAs. We investigated extent pattern in sequence data domain III (DIII) envelope (E) gene serial plasma samples (n = 49) taken...
Takeda has developed a live-attenuated dengue tetravalent vaccine candidate (TAK-003) which been shown to be immunogenic with acceptable reactogenicity in phase 1 trials. In agreement World Health Organization prequalification requirements for vaccines, manufactured lyophilized formulation of TAK-003 that allows stable storage at +2°C +8°C. This randomized, double-blind, 2 study (NCT02193087) was performed 1002 healthy dengue-naïve adults, 18–49 years age, across seven centers the USA...
As robust dengue-specific CD4+ and CD8+ T cell responses are essential for protective immunity, we assessed cell-mediated immune (CMI) to a DENV-2-based dengue tetravalent vaccine candidate (TAK-003) in adolescents living Panama, dengue-endemic country. Peripheral blood mononuclear cells were collected from subset of 67 participants ≥ 10 years old included phase 2 clinical trial TAK-003 (Clinicaltrials.gov: NCT02302066). Following stimulation with peptides, the frequency, magnitude,...
Immunobridging is an important methodology that can be used to extrapolate vaccine efficacy estimates populations not evaluated in clinical studies, and has been successfully developing many vaccines. Dengue, caused by a mosquito-transmitted flavivirus endemic tropical subtropical regions, traditionally thought of as pediatric disease but now global threat both children adults. We bridged immunogenicity data from phase 3 study tetravalent dengue (TAK-003), performed adolescents living areas,...
Background Although rabies represents an important public health threat, it is still a neglected disease in Asia and Africa where causes tens of thousands deaths annually despite available human animal vaccines. In the Central African Republic (CAR), endemic country for rabies, this remains poorly investigated. Methods To evaluate extent threat that poses CAR, we analyzed data 2012 from National Reference Laboratory Rabies, laboratory confirmation was performed by immunofluorescence PCR both...